Patents by Inventor Andrew Charles Good

Andrew Charles Good has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis C virus inhibitors
    Publication number: 20080152619
    Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: May 9, 2006
    Publication date: June 26, 2008
    Inventors: Ny Sin, Paul Michael Scola, Nicholas A. Meanwell, Xiangdong Alan Wang, Li-Qiang Sun, Jie Chen, Andrew Charles Good
  • Hepatitis C virus inhibitors
    Patent number: 7323447
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: January 29, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ny Sin, Andrew Charles Good, Brian Lee Venables, Paul Michael Scola, Nicholas A. Meanwell
  • Hepatitis C virus inhibitors
    Patent number: 7309708
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: December 18, 2007
    Assignee: Birstol-Myers Squibb Company
    Inventors: Yong Tu, Paul Michael Scola, Andrew Charles Good, Jeffrey Allen Campbell
  • Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
    Patent number: 7173004
    Abstract: Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Fiona McPhee, Jeffrey Allen Campbell, Stanley D'Andrea, Zhizhen Barbara Zheng, Andrew Charles Good, David J. Carini, Barry L. Johnson, Paul Michael Scola, Kenneth M. Boy
  • Hepatitis C virus inhibitors
    Patent number: 7041698
    Abstract: The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: May 9, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Amy Ripka, Jeffrey Allen Campbell, Andrew Charles Good, Paul Michael Scola, Ny Sin, Brian Venables
  • Hepatitis C virus inhibitors
    Patent number: 6995174
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: February 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell
  • Heterocyclicsulfonamide hepatitis C virus inhibitors
    Patent number: 6869964
    Abstract: The present invention relates to tripeptide compounds, compositions containing such compounds and methods for using such compounds for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: March 22, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey Allen Campbell, Andrew Charles Good
  • Inhibitors of hepatitis C virus
    Patent number: 6867185
    Abstract: The present invention relates to macrocyclic compounds, methods for making these compounds, pharmaceutical compositions and the therapeutic or prophylactic use of these compounds by administering said compounds to mammals or treat hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: March 15, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey Allen Campbell, Andrew Charles Good
  • Hepatitis C virus inhibitors
    Publication number: 20040106559
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: 1
    Type: Application
    Filed: May 20, 2003
    Publication date: June 3, 2004
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell
  • Heterocyclicsulfonamide hepatitis C virus inhibitors
    Publication number: 20040072761
    Abstract: The present invention relates to tripeptide compounds, compositions containing such compounds and methods for using such compounds for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
    Type: Application
    Filed: May 20, 2003
    Publication date: April 15, 2004
    Inventors: Jeffrey Allen Campbell, Andrew Charles Good
  • Hepatitis C virus inhibitors
    Publication number: 20040048802
    Abstract: The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
    Type: Application
    Filed: May 20, 2003
    Publication date: March 11, 2004
    Inventors: Amy Ripka, Jeffrey Allen Campbell, Andrew Charles Good, Paul Michael Scola, Ny Sin, Brian Venables
  • Inhibitors of hepatitis C virus
    Publication number: 20040038872
    Abstract: The present invention relates to macrocyclic compounds, methods for making these compounds, pharmaceutical compositions and the therapeutic or prophylactic use of these compounds by administering said compounds to mammals to prevent or treat hepatitis C virus (HCV) infection.
    Type: Application
    Filed: December 12, 2002
    Publication date: February 26, 2004
    Inventors: Jeffrey Allen Campbell, Andrew Charles Good